Global Mouth-dissolving Tablets Market Size By Type (Anti-Psychotics Drug, Anti-Epileptics Drug), By Application (CNS Diseases, Gastrointestinal Diseases), By Region, And Segment Forecasts, 2023 to 20...

The Global Mouth-dissolving Tablets Market was valued at USD 9.1 billion in 2023 and is expected to reach USD 15.8 billion by 2031, growing at a CAGR of 7.0% during the forecast period from 2023 to 2031. The market growth is driven by increasing patient compliance for non-invasive drug delivery methods, rising demand for rapid-onset therapeutics, and the growing prevalence of diseases requiring quick treatment responses such as pain, nausea, and neurological conditions. The convenience, faster disintegration time, and avoidance of first-pass metabolism make mouth-dissolving tablets (MDTs) an attractive formulation across various therapeutic segments.

Drivers:

1. Rising Demand for Patient-friendly Dosage Forms:

Mouth-dissolving tablets are highly preferred among pediatric, geriatric, and psychiatric patient groups due to their ease of administration without the need for water or swallowing. This growing preference is significantly boosting market demand.

2. Increasing Prevalence of Chronic and Acute Conditions:

The expanding base of patients with chronic diseases such as hypertension, migraine, and depression—along with acute conditions like allergic reactions and motion sickness—is driving the uptake of MDTs for rapid therapeutic action.

3. Pharmaceutical Innovation and R&D Investments:

Continuous advancements in drug delivery technologies and bioavailability enhancers have led to the development of more effective MDT formulations, fueling market growth.

Restraints:

1. Limited Drug Load Capacity:

MDTs are suitable only for drugs with lower dosage requirements. Formulating drugs that require a high dose in MDTs remains challenging, thereby restricting their applicability to certain drug categories.

2. Stability Issues and Production Costs:

MDTs are sensitive to humidity and require specialized packaging to maintain stability, increasing the production and distribution costs for manufacturers.

Opportunity:

1. Expanding OTC (Over-the-Counter) Drug Segment:

The growth of the OTC drug market, particularly in digestive health, allergy relief, and pain management, offers promising opportunities for MDT formulations that cater to self-medication trends.

2. Market Penetration in Emerging Economies:

Increasing healthcare access and awareness in countries across Asia-Pacific, Latin America, and Africa are opening new growth avenues for MDTs, especially in rural or resource-limited settings.

Market by System Type Insights:

Based on system type, the Orally Disintegrating Tablets (ODTs) segment held the largest market share in 2023. ODTs dominate due to their established use, improved patient adherence, and technological developments like taste masking and nano-carriers. This segment is projected to maintain dominance throughout the forecast period as pharmaceutical companies continue innovating palatable, fast-acting formulations.

Market by End-use Insights:

In 2023, the Retail Pharmacies segment accounted for the largest revenue share, driven by the surge in self-medication and OTC purchases. However, Hospitals and Clinics are also emerging as significant distribution channels due to increasing prescriptions of MDTs for inpatients and post-surgical care requiring fast relief medications.

Market by Regional Insights:

North America led the global mouth-dissolving tablets market in 2023, attributed to advanced healthcare infrastructure, higher prevalence of lifestyle-related diseases, and strong pharmaceutical R&D. Asia-Pacific is expected to witness the fastest growth during the forecast period, propelled by rising healthcare expenditure, increasing chronic disease burden, and greater acceptance of novel dosage forms in countries like India and China.

Competitive Scenario:

Leading players in the global mouth-dissolving tablets market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., GlaxoSmithKline plc, Bayer AG, Eli Lilly and Company, Cipla Ltd., and Dr. Reddy’s Laboratories Ltd. These companies are focused on product development, patenting new formulations, and strategic mergers to expand market share. For example:

In 2023, Novartis introduced a new MDT formulation of a cardiovascular drug aimed at elderly patients with dysphagia.

In 2024, Sun Pharma partnered with a U.S.-based biotech firm to co-develop fast-dissolving CNS drugs using nanotechnology.

Pfizer expanded its manufacturing capabilities in Asia-Pacific to meet the rising demand for orally disintegrating tablets across the region.

Scope of Work – Global Mouth-dissolving Tablets Market

Key Market Developments:

January 2023 – Teva Pharmaceuticals launched a generic MDT version of a popular antihistamine in North America, targeting the allergy season surge.

July 2024 – Cipla introduced a mouth-dissolving formulation of paracetamol tailored for pediatric use in India and Sub-Saharan Africa.

March 2025 – Dr. Reddy’s received USFDA approval for its MDT variant of an anti-epileptic drug, enhancing its neurology portfolio.

FAQs:

1) What is the current market size of the Global Mouth-dissolving Tablets Market?

The market size was valued at USD 9.1 billion in 2023.

2) What is the major growth driver of the Global Mouth-dissolving Tablets Market?

The key driver is the rising demand for patient-friendly, fast-acting oral dosage forms.

3) Which is the largest region during the forecast period in the Global Mouth-dissolving Tablets Market?

North America held the largest market share in 2023, while Asia-Pacific is expected to grow fastest.

4) Which segment accounted for the largest market share in the Global Mouth-dissolving Tablets Market?

The Orally Disintegrating Tablets (ODTs) segment led the market by system type.

5) Who are the key market players in the Global Mouth-dissolving Tablets Market?

Key players include Pfizer Inc., Teva Pharmaceutical, Novartis, Sun Pharma, GSK, Bayer, Cipla, and Dr. Reddy’s Laboratories.